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Purpose: The aim of this study was to determine the suitability of serum prolyl hydroxylase-3 (PHD3) as a diagnostic or monitoring 
biomarker of renal cell carcinoma (RCC).
Materials and Methods: Between October 2013 and March 2015, we prospectively recruited study participants. The RCC group 
consisted of 56 patients who underwent radical or partial nephrectomy. The control group included 56 healthy kidney donors and 
13 patients with benign renal masses. Blood from the RCC patients was sampled prior to surgery and again 1 and 3 months after 
the operation. Serum PHD3 levels were measured via enzyme-linked immunosorbent assay and compared between RCC patients 
and controls. 
Results: RCC patients had higher serum PHD3 levels than controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL, p=0.023), with an area 
under curve (AUC) of 0.668. With a cutoff value of 0.761 ng/ml, the sensitivity, specificity, positive predictive value, and negative 
predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, respectively. No significant difference in PHD3 level was observed between 
healthy kidney donors and patients with benign renal masses. The predictive performance of PHD3 was improved in subgroup 
analyses of RCC patients with a tumor size >2 cm (n=40) or clear-cell histology (n=44), with AUCs of 0.709 and 0.688, respec-
tively. Among 37 patients with PHD3 levels greater than the cutoff value of 0.761 ng/mL, the postoperative PHD3 levels at 1 and 3 
months were significantly lower than the preoperative PHD3 levels (both p<0.001).
Conclusions: Serum PHD3 represents a novel RCC biomarker that shows acceptable diagnostic performance.
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INTRODUCTION
Currently, most cases of renal cell carcinoma (RCC) are 
detected incidentally, as no clinically relevant biomarker is 
available. Patients with symptoms have often progressed to 
an advanced stage of the disease and thus have poor onco-
logic outcomes. Diagnosis of RCC typically depends on radio-
logic features. In some cases, invasive renal biopsy is used to 
differentiate renal malignancies from benign renal masses. 
Patients in which small renal masses are detected early are 
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candidates for nephron-sparing procedures, which decrease 
the risks of  chronic kidney disease and cardiovascular 
events [1]. The significant risk of poor outcomes in patients 
with delayed diagnosis of RCC suggests that a reliable bio-
marker is urgently needed. 
Hypoxia-inducible factor (HIF) is a key regulator of 
pathogenesis in RCC. HIF regulates at least 500 to 1,000 
genes involved in angiogenesis, glucose metabolism, stimula-
tion of growth factors, and cell cycle control [2,3]. Although 
the stability of the HIF expression in most RCC cells is en-
hanced due to the inactivation of the von Hippel–Lindau 
(VHL) gene, HIF is rapidly degraded in normal cells via 
proteasomal degradation [4]. Prolyl hydroxylase (PHD) plays 
a role in the HIF degradation process via oxygen-dependent 
hydroxylation [5]. The PHD family enzymes (PHD1–3) share 
a conserved C-terminal hydroxylase domain, but each PHD 
isoform differs in function and tissue-specific expression 
pattern [6]. PHD3 reportedly plays a role in several types of 
cancer [7,8]. Previous studies have shown that PHD3 is over-
expressed in RCC, suggesting that PHD3 might serve as a 
biomarker of this disease [9-11]. In the present study, we ex-
amined the serum levels of PHD3 in a prospectively enrolled 
cohort including both RCC patients and healthy controls. 
We aimed to assess the suitability of serum PHD3 as a diag-
nostic or surveillance biomarker of RCC.
MATERIALS AND METHODS
1. Study participants
Between October 2013 and March 2015, we prospectively 
recruited participants after obtaining approval from the 
Institutional Review Board of  Severance Hospital (IRB 
no. 4-2013-0166). Informed consent was obtained from all 
participants before enrollment in the study. All the study 
protocols were carried out in accordance with the Declara-
tion of Helsinki Guidelines. The RCC group consisted of 56 
patients who underwent radical or partial nephrectomy for 
RCC during the study period. The control group included 
56 healthy kidney donors and 13 patients with benign renal 
masses. All RCC and benign renal neoplasm diagnoses were 
pathologically confirmed by surgical resection. The benign 
renal neoplasms included five angiomyolipomas, four onco-
cytomas, three adenomas, and one case of pyelonephritis. 
2. Preparation of blood samples
Blood was sampled from the RCC patients and controls 
preoperatively on the day of surgery. To investigate serial 
changes in PHD3 levels, blood was sampled again 1 and 3 
months postoperatively in the RCC group. The blood samples 
were centrifuged for 15 minutes at 1,000g within 30 minutes 
of collection, and the serum was then divided into aliquots 
and stored at -80ºC.
3. Enzyme-linked immunosorbent assay (ELISA) 
for PHD3
For each serum sample, the PHD3 level was analyzed 
using ELISA. Anti-PHD3 antibody was purchased from Ab-
Frontier (mouse monoclonal 28A1, Seoul, Korea). Serum was 
diluted 2-fold before analysis. Recombinant PHD3 protein 
and diluted serum were coated onto the surface of 96-well 
ELISA plates overnight at 4ºC with 0.1 M sodium bicarbon-
ate buffer (pH 9.6). The coated plates were blocked with 5% 
skim milk in Tris-buffered saline (TBS) for 1 hour at 37ºC. 
After washing with TBS, the wells were then incubated 
with primary antibody (diluted 1:500 in blocking solution) 
for 2 hours and subsequently washed and incubated with 
secondary antibody (diluted 1:3,000 in blocking solution) for 1 
hour. After a final washing step, 50 μL of tetramethylbenzi-
dine substrate was added to each well, and the reaction was 
stopped by the addition of 1 N H2SO4. Absorbance was deter-
mined at 495 nm using a spectrophotometer. All assays were 
performed in duplicate.
4. Statistical analysis
To investigate the effects of age and sex on serum PHD3 
level, the results in the control group were analyzed accord-
ing to sex and age (≤50 years vs. >50 years). As the patients 
in the RCC group were significantly older than the partici-
pants in the control group, we performed multivariate lin-
ear regression analysis to evaluate whether the presence of 
RCC affects the serum level of PHD3 independently of age. 
In the RCC group, changes in the serum PHD3 level were 
evaluated according to tumor size, pathologic stage, Fur-
mann grade, and histology. To evaluate the diagnostic utility 
of serum PHD3 level, quantification results were compared 
between the RCC and control groups. Receiver operating 
characteristic (ROC) curves were constructed, and the data 
were analyzed based on the area under the curve (AUC). 
The optimal cutoff value (indicating maximum sensitivity 
and specificity) was calculated using the Youden index. ROC 
curves were also generated for subgroups of RCC patients 
with tumor size >2 cm or clear-cell histology. To investigate 
the utility of serum PHD3 level for RCC monitoring, PHD3 
levels were compared pre- and postoperatively. Differences in 
quantitative values were compared using Student’s t-test or 
one-way ANOVA. Differences in qualitative variables were 
compared using the chi-square test or Fisher’s exact test. 
Preoperative and postoperative PHD3 levels were compared 
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using the paired t-test. Statistical analyses were performed 
using the PASW Statistics for Windows version 18.0 (SPSS 
Inc., Chicago, IL, USA). A p-value <0.05 was considered in-
dicative of statistical significance, and all p-values were two-
sided. ROC analyses and graphics plotting were performed 
using R, version 3.2.5 (https://www.r-project.org).
RESULTS
1. Patient characteristics
The characteristics of the study cohort are summarized 
in Table 1. The control group consisted of 56 healthy kidney 
donors and 13 patients with benign renal masses. Patients 
in the RCC group were significantly older than the controls. 
However, the PHD3 level did not differ according to age (≤50 
vs. >50 years, 0.73±0.09 ng/mL vs. 0.73±0.10 ng/mL; p>0.05) 
or sex (male vs. female, 0.73±0.09 ng/mL vs. 0.74±0.10 ng/mL; 
p>0.05). Additionally, no significant difference in PHD3 level 
was observed between healthy kidney donors and patients 
with benign renal masses (healthy donors vs. benign renal 
mass patients, 0.73±0.09 ng/mL vs. 0.73±0.09 ng/mL; p>0.05). 
Of the 56 patients with RCC, 43 (76.8%) had T1a disease, 
and 44 (78.6%) had clear-cell histology RCC. Non-significant 
trends of higher PHD3 levels were observed in patients with 
larger-size, higher-grade, and T2-stage tumors, and in those 
with clear-cell histology (Table 2).
2. Diagnostic performance of PHD3
RCC patients had higher serum PHD3 levels than the 
controls (0.79±0.17 ng/mL vs. 0.73±0.09 ng/mL; p=0.023) (Fig. 
1A). In the multivariate linear regression analysis, presence 
of RCC significantly affected the PHD3 serum level regard-
less of age (Table 3). Analyses of ROC curves for all cases 
(n=56) versus all controls (n=69) revealed an AUC for PHD3 
of 0.668 (95% CI, 0.565–0.769) (Fig. 1B). Using a cutoff value 
of 0.761 ng/mL, as calculated according to the Youden index, 
the sensitivity, specificity, positive predictive value, and 
negative predictive value were 66.1%, 68.1%, 28.8%, and 37.3%, 
respectively. ROC curve analyses were also performed for 
subgroups of RCC cases. The PHD3 AUCs for patients with 
tumor size >2 cm (n=40) and patients with clear-cell histol-
ogy (n=44) were 0.709 and 0.688, respectively.
3. Serial changes in serum PHD3 level after sur-
gery in RCC patients
The mean PHD3 level in the RCC patients at postopera-
tive months 1 and 3 had decreased from the preoperative 
level (Fig. 2A). For the 37 patients with PHD3 levels greater 
than the cutoff value of 0.761 ng/mL, the level was decreased 
in 33 patients (89.2%) at postoperative month 1, and in 31 
patients (83.8%) at postoperative month 3 (Fig. 2B). Paired t-
test analyses revealed that the PHD3 levels at postoperative 
months 1 and 3 were significantly lower than the preopera-
tive PHD3 levels (both p<0.001). 
Table 1. Clinical and pathological characteristics of the study cohort
Characteristic RCC (n=56) Control (n=69) p-value
Age (y)
   Mean±SD 52.9±12.6 48.5±9.3 0.024
   Median (IQR) 54 (44–62) 49 (42–57)
Sex, n (%) 0.852
   Male 35 (62.5) 42 (60.9)
   Female 21 (37.5) 27 (39.1)
Size (cm)
   Mean±SD 3.64±3.36
   Median (IQR) 2.7 (2–3.8)
Stage, n (%)
   T1a 43 (76.8)
   T1b 6 (10.7)
   T2a 2 (3.6)
   T2b 2 (3.6)
   T3a 3 (5.4)
Furmann grade, n (%)
   I–II 36 (64.3)
   III–IV 20 (35.7)
Cell type, n (%)
   Clear cell 44 (78.6)
   Non-clear 12 (21.4)
RCC, renal cell carcinoma; SD, standard deviation; IQR, interquartile 
range.
Table 2. Serum PHD3 level according to tumor characteristics in pa-
tients with renal cell carcinoma
 Characteristic Serum PHD3 level p-value
Tumor size (cm) 0.161
   ≤2 (n=16) 0.75±0.21
   >2, ≤4 (n=27) 0.78±0.17
   >4 (n=13) 0.87±0.06
Stage 0.15
   T1 (n=49) 0.78±0.17
   >T2 (n=7) 0.88±0.05
Furmann grade 0.086
   I–II (n=36) 0.76±0.16
   III–IV (n=20) 0.84±0.17
Cell type 0.535
   Clear cell (n=44) 0.80±0.18
   Non-clear (n=12) 0.76±0.12
Values are presented as mean±standard deviation.
PHD3, prolyl hydroxylase-3.
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DISCUSSION
The results of the present study revealed that PHD3 lev-
els are significantly higher in RCC patients than in healthy, 
cancer-free individuals. PHD3 levels did not differ by age, 
sex, or presence/absence of benign renal masses. In addition, 
although not statistically significant, correlations of PHD3 
level with tumor size, stage, and grade were observed, indi-
cating that this marker can potentially reflect tumor burden 
and/or aggressiveness. The diagnostic performance of PHD3 
was improved when considering only those patients with tu-
mor size >2 cm. An active surveillance cohort study reported 
no association between a tumor size <2 cm and delayed in-
tervention [12]. We suggest that measurement of the PHD3 
level will yield superior diagnostic accuracy in significant 
RCC.
Multiple potential RCC biomarkers have been inves-
tigated for diagnostic or monitoring purposes [13-16]. The 
HIF pathway plays an important role in the development 
of RCC, and recent studies have demonstrated that down-
stream molecules of HIF such as carbonic anhydrase IX or 
angiopoietin-like 4 could be utilized as biomarkers of RCC 
[13]. PHDs are also closely related to HIF signaling, which is 
critical in the hypoxic conditions of the tumor microenviron-
ment. Under normoxic conditions, PHDs inactivate HIFs via 
hydroxylation of a specific domain, resulting in the binding 
of VHL to HIF and subsequent proteasomal degradation [5,17]. 
In contrast, PHD activity decreases under hypoxic condi-
tions, and subsequent HIF accumulation leads to the expres-
sion of HIF target genes, enabling tumor cells to survive 
under hypoxic conditions.
The role of PHD3 has been examined in multiple human 
cancers such as pancreatic, gastric, breast, and colorectal 
cancer [7,8,18,19]. In most studies, PHD3 plays a tumor-sup-
pressive role by promoting apoptosis of tumor cells [7,8,18-20]. 
The level of PHD3 expression is also associated with favor-
able oncologic outcomes in RCC [21]. Another study involving 
lung cancer, however, suggested a tumor-promoting function 
of PHD3 [22]. The mechanism underlying the effect of PHD3 
on tumor progression has yet to be fully elucidated. PHD3 
may enhance cell cycle progression and the survival of 
cancer cells by decreasing the stability of cyclin-dependent 
kinase inhibitor p27 or through involvement in glucose me-
tabolism [7,8,18,19]. A recent study suggested that PHD3 plays 
a role in the maintenance of the high glycolytic rate, as well 
as lactate production, in clear-cell RCC, thus contributing to 
tumor progression [23].
A previous transcriptional study showed that PHD3 
expression is highly up-regulated in RCC tissues compared 
with that in normal kidney tissues [11]. Sato et al. [10] re-
ported that PHD3 is a potent immunogenic antigen in RCC. 
In a subsequent study, researchers d discovered that the se-
rum anti-PHD3 antibody levels in RCC patients are signifi-
cantly higher than those in healthy controls. These results 
were similar to those of our study. Nevertheless, our study 
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Fig. 1. (A) Difference in serum prolyl hydroxylase-3 (PHD3) levels between renal cell carcinoma (RCC) patients and controls. The control group included
both healthy kidney donors and patients with benign renal masses. (B) Receiver operating characteristic curve for PHD3 comparing RCC patients (n=56)
and controls (n=69). The AUC for PHD3 was 0.668 (95% confidence interval, 0.565–0.769).
Table 3. Multivariate linear regression analysis to evaluate whether 
presence of renal cell carcinoma (RCC) independently affects serum 
PHD3 level
Univariate Multivariate
β p-value β p-value
Age 0.065 0.472 0.022 0.808
RCC (vs. control) 0.218 0.015 0.213 0.020
PHD3, prolyl hydroxylase-3.
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has several advantages over prior studies. First, our study 
included patients with benign renal masses in the control 
group, and we demonstrated that PHD3 could be utilized 
for differentiation between malignant and benign renal 
masses. Second, the current study included more than twice 
the number of participants in the study by Tanaka et al. [9]. 
We also investigated the association between PHD3 and age, 
sex, and tumor characteristics such as mass size, stage, and 
histology.
Most studies on the relationship between HIF and PHD3 
have been performed on clear-cell RCC. Although increasing 
evidence supports a role of HIF in other types of RCC, PHD3 
expression in non-clear-cell RCC is not widely reported [24]. 
In our study, the PHD3 level was higher in patients with 
non-clear-cell RCC than in the healthy controls. Overexpres-
sion of PHD3 in papillary RCC was demonstrated in a pre-
vious study, using immunohistochemistry, indicating that 
the expression of PHD3 might be independent of mutations 
in the VHL gene [10]. Although no statistically significant 
relationship was observed due to the small number of pa-
tients with non-clear-cell RCC, the results suggest that PHD3 
might be informative in the diagnosis of this RCC type. This 
theory should be explored in further research involving 
more patients with non-clear-cell RCC than that in the cur-
rent study.
Our study is not devoid of limitations. First, the control 
group had few benign renal masses and did not include pa-
tients with other malignancies. Although upregulation of 
PHD3 expression in other malignancies has been reported, 
data from the cBioPortal (http://www.cbioportal.org) [25] 
showed that PHD3 expression is extremely high in RCC (Fig. 
3). We believe that PHD3 might be a more specific marker 
of RCC. Second, we observed patients with RCC who had 
PHD3 levels comparable to those of healthy controls, which 
might reflect low tumor burden or inter-individual differ-
ences in PHD3 expression. Additional VHL and HIF genetic 
Fig. 2. (A) Serial changes in serum prolyl hydroxylase-3 (PHD3) levels after surgery in all patients. (B) Patients with preoperative serum PHD3 levels >0.761 
ng/mL. (B) Preoperative and postoperative PHD3 levels were compared using paired t-test.
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profiling data could help identify factors associated with 
the expression of PHD3. Third, we did not investigate the 
association between the PHD3 level and prognosis. During 
follow-up, which had a median duration of 27 months, only 
2 patients experienced recurrence, which was an insufficient 
number for statistical analysis. A prolonged follow-up study 
in patients with more advanced stages of RCC is required 
to evaluate the prognostic value of PHD3. Fourth, there was 
significant difference in age between the RCC and control 
groups, as the control group mainly consisted of healthy 
kidney donors. However, the PHD3 level did not differ ac-
cording to age in the control group and age did not affect 
the level of PHD3 in multivariate analysis (Table 3). The 
last limitation of our study protocol is that it did not include 
postoperative blood sampling in the control group. Thus, 
we cannot exclude the effect of renal volume reduction on 
the postoperative decrease in serum PHD3 level in the RCC 
group. 
CONCLUSIONS
Serum PHD3 can serve as a novel biomarker of RCC 
diagnosis and postsurgical monitoring, and shows acceptable 
diagnostic performance. It can also help differentiate RCC 
from benign renal masses. Although our findings should be 
validated in a larger cohort, serum PHD3 appears to be suit-
able for clinical application in diagnosing and monitoring 
patients with RCC.
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